A study of 545 women ages 25 to 50 years showed that the use of Provista Diagnostics' Videssa Breast assay in breast cancer detection may lower biopsy use by up to 67%. The multiprotein biomarker blood test was found to have 87.5% sensitivity, 83.8% specificity, 99.1% negative predictive value and 25.2% positive predictive value.
Study shows promising results for Provista's blood test for breast cancer
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.